BACKGROUND: We surveyed the natural history of bone metastases in patients affected by soft tissue sarcoma (STS). METHODS: This multicenter retrospective observational study included 135 patients. Histological subtype, characteristics of bone metastases, treatment, skeletal related events (SREs) and disease outcome were recorded. RESULTS: The most represented histological subtypes were leiomyosarcoma (27%) angiosarcoma (13%) and undifferentiated sarcoma (8%). Axial skeleton was the most common site for bone involvement (70%). In 27% of cases, bone metastases were present at the time of diagnosis. Fifty-four (40%) patients developed SREs and the median time to first SRE was 4 months (range 1-9). The most common SRE was the need for radiotherapy (28%) followed by pathological fracture (22%). Median survival after bone progression was 6 months (range 1-14). SREs were associated with decreased overall survival (OS) (P = 0.04). A subgroup analysis revealed that bisphosphonates significantly prolonged median time to first SRE (5 versus 2 months; P = 0.002) while they did not determine an improvement in OS, although a favourable trend was identified (median: 7 versus 5 months; P = 0.105). CONCLUSIONS: This study illustrates the burden of bone disease from STS and supports the use of bisphosphonates in this setting.

Vincenzi, B., Frezza, A.M., Schiavon, G., Santini, D., Dileo, P., Silletta, M., et al. (2013). Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. CLINICAL SARCOMA RESEARCH, 3 [10.1186/2045-3329-3-6].

Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options

BADALAMENTI, Giuseppe;
2013

Abstract

BACKGROUND: We surveyed the natural history of bone metastases in patients affected by soft tissue sarcoma (STS). METHODS: This multicenter retrospective observational study included 135 patients. Histological subtype, characteristics of bone metastases, treatment, skeletal related events (SREs) and disease outcome were recorded. RESULTS: The most represented histological subtypes were leiomyosarcoma (27%) angiosarcoma (13%) and undifferentiated sarcoma (8%). Axial skeleton was the most common site for bone involvement (70%). In 27% of cases, bone metastases were present at the time of diagnosis. Fifty-four (40%) patients developed SREs and the median time to first SRE was 4 months (range 1-9). The most common SRE was the need for radiotherapy (28%) followed by pathological fracture (22%). Median survival after bone progression was 6 months (range 1-14). SREs were associated with decreased overall survival (OS) (P = 0.04). A subgroup analysis revealed that bisphosphonates significantly prolonged median time to first SRE (5 versus 2 months; P = 0.002) while they did not determine an improvement in OS, although a favourable trend was identified (median: 7 versus 5 months; P = 0.105). CONCLUSIONS: This study illustrates the burden of bone disease from STS and supports the use of bisphosphonates in this setting.
Settore MED/06 - Oncologia Medica
http://www.clinicalsarcomaresearch.com/content/3/1/6
Vincenzi, B., Frezza, A.M., Schiavon, G., Santini, D., Dileo, P., Silletta, M., et al. (2013). Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. CLINICAL SARCOMA RESEARCH, 3 [10.1186/2045-3329-3-6].
File in questo prodotto:
File Dimensione Formato  
Bone metastases in soft tissue sarcoma.pdf

accesso aperto

Dimensione 156.92 kB
Formato Adobe PDF
156.92 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/104474
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 14
social impact